The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

18 May 2021 14:33

RNS Number : 0340Z
Immunodiagnostic Systems Hldgs PLC
18 May 2021
 

Immunodiagnostic Systems Holdings PLC  

Director/PDMR Dealing

18 May 2021

Immunodiagnostic Systems Holdings PLC ("IDS") a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical and research markets, announces that it has granted the following options to persons discharging managerial responsibilities to acquire ordinary shares of 2p in the capital of the Company under the Company's Co-Investment Executive Option Scheme ("Scheme").

Employee

Position

Grant Date

Number of Options

Exercise Price

Jaap Stuut

Chief Executive Officer

17-May-21

7,500

1.95

Paul Martin

Chief Financial Officer

17-May-21

6,300

2.75

17-May-21

6,000

1.95

Nicola Trewin

Group HR Director

17-May-21

3,000

1.95

Soenke Weissenborn

Group Operations Director

17-May-21

6,000

2.49

17-May-21

6,000

2.27

 

Under this Scheme, participants who purchase ordinary shares in the Company ("Co-Investment Shares") are entitled to three share options for each Co-Investment Share they purchase. The exercise price for the options is set at the price the participant paid for each Co-Investment Share. 

The options are subject to the satisfaction of performance conditions and vest after a period of 3 years for the date of purchase of the Co-Investment Share. The options are exercisable over the period of 10 years from the date of grant.

In accordance with the operation of the Scheme in previous years, option awards were due to be granted on 31 March 2021 related to Co-Investment Shares purchased or rolled over in the financial year ended 31 March 2021, however this was not possible owing to the Company being in a close period.

All options granted at this time will be exercisable in full shortly prior to the scheme of arrangement to be implemented to effect the recommended cash offer for IDS by PerkinElmer (UK) Holdings Ltd (as referred to in the announcement made yesterday) becoming effective.

The below notifications, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, gives further detail of the number of options awarded.

For further information:

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Paul Martin, Group Finance Director

 

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

Victoria Erskine

 

 

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

1. Jaap Stuut

2. Paul Martin

3. Nicola Trewin

4. Soenke Weissenborn

2.

Reason for the notification

a.

Position/status

1. Chief Executive Officer

2. Chief Financial Officer

3. Group HR Director

4. Group Operations Director

 

b.

Initial notification

/Amendment

Initial

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Immunodiagnostic Systems Holdings plc

b.

LEI

213800HZMYTD4NGF4L78

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument,

 

type

of instrument

 

Identification code

Options over ordinary shares of 2p each in Immunodiagnostic Systems Holdings plc

 

Ordinary shares

 

 

GB00B01YZ052

b.

Nature of the transaction

Grant of Options

 

 

c.

Price(s) and volume(s)

Employee

Grant Date

Number of Options

Exercise Price

Jaap Stuut

17-May-21

7,500

1.95

Paul Martin

17-May-21

6,300

2.75

17-May-21

6,000

1.95

Nicola Trewin

17-May-21

3,000

1.95

Soenke Weissenborn

17-May-21

6,000

2.49

17-May-21

6,000

2.27

 

 

d.

Aggregated information

· Aggregated volume

· Price

 

 

Employee

Grant Date

Number of Options

Weighted Average Exercise Price

Paul Martin

17-May-21

12,300

2.360

Soenke Weissenborn

17-May-21

12,000

2.380

 

 

e.

Date of the transaction

17-May-21

f.

Place of the transaction

Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBXGDUGXBDGBI
Date   Source Headline
1st Jun 20117:00 amRNSAppointment of Non-Executive Director
9th May 20117:00 amRNSChange of contract terms
28th Apr 20117:00 amRNSTotal Voting Rights
12th Apr 20118:34 amRNSExercise of Share Options and Total Voting Rights
6th Apr 20117:00 amRNSTrading update
28th Mar 20117:35 amRNSExclusive Licence Agreement
1st Mar 20117:00 amRNSDirector/PDMR Shareholding
3rd Feb 201110:34 amRNSDirector/PDMR Shareholding
11th Jan 20113:40 pmRNSDirector/PDMR Shareholding
30th Nov 20107:00 amRNSHalf Yearly Report
12th Nov 20104:41 pmRNSSecond Price Monitoring Extn
12th Nov 20104:35 pmRNSPrice Monitoring Extension
1st Nov 201011:22 amRNSHolding(s) in Company
5th Oct 20108:56 amRNSPosting of Report and Accounts and Notice of AGM
5th Oct 20107:00 amRNSTrading Update
27th Sep 20107:00 amRNSIssue of Equity
21st Sep 20104:35 pmRNSPrice Monitoring Extension
20th Sep 201010:33 amRNSHolding(s) in Company
13th Sep 20107:00 amRNSAcquisition & Research Agreement
25th Aug 20104:06 pmRNSResult of AGM
25th Aug 20107:00 amRNSAGM Statement
26th Jul 20101:00 pmRNSExercise of Share Options and Total Voting Rights
26th Jul 20107:00 amRNSNew specialist assay launched for IDS-iSYS
20th Jul 20107:00 amRNSDirector/PDMR Shareholding
12th Jul 20107:00 amRNSDirectorate Change
12th Jul 20107:00 amRNSFinal Results
29th Jun 20107:00 amRNSReceipt of FDA 510(k) clearances
16th Jun 20104:40 pmRNSSecond Price Monitoring Extn
16th Jun 20104:35 pmRNSPrice Monitoring Extension
14th Jun 20104:35 pmRNSPrice Monitoring Extension
11th Jun 20104:35 pmRNSPrice Monitoring Extension
10th Jun 20104:35 pmRNSPrice Monitoring Extension
26th May 20104:40 pmRNSSecond Price Monitoring Extn
26th May 20104:35 pmRNSPrice Monitoring Extension
10th May 20107:00 amRNSExercise of Share Options
12th Apr 20107:00 amRNSTrading Statement
31st Mar 201012:24 pmRNSTotal Voting Rights
31st Mar 20107:00 amRNSNew specialist assays launched for IDS-iSYS
22nd Mar 20107:00 amRNSDirector/PDMR Shareholding
16th Mar 201010:00 amRNSDirector/PDMR Shareholding
23rd Feb 201011:47 amRNSExercise of Share Options
9th Feb 20107:00 amRNSShare options
1st Feb 20109:13 amRNSExercise of Share Options and Total Voting Rights
4th Jan 20107:00 amRNSFive year distribution agreement
21st Dec 20091:15 pmRNSDirector/PDMR Shareholding
18th Dec 20093:18 pmRNSIssue of Equity
11th Dec 20097:00 amRNSDirectorate Change
10th Dec 20097:00 amRNSExercise of Share Options and Directors' Dealings
30th Nov 20097:00 amRNSHalf Yearly Report
18th Nov 200910:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.